Utmb-novartis alliance for pandemic preparedness - overall
Ended Cooperative Agreement Awarded Last action
- Award ID
- U19AI171413
- Recipient
-
University Of Texas Medical Branch At Galveston UEI MSPWVMXXMN76
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $29,811,287
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Place of performance
- Texas, USA
Award details come from USAspending.gov.
Description
- Abstract
- Pandemic prevention and preparedness is a major scientific and societal priority that requires sustained and forward looking investments across governmental, non-governmental, academic and private sectors to develop an arsenal of countermeasures against the existential threat of viral pandemics. Combining world-leading BSL3/4 capabilities at university of texas of medical branch (utmb) and state-of-the art drug discovery technologies at novartis, the utmb novartis alliance for pandemic preparedness (unapp), is a unique and innovative partnership that brings together the multi-disciplinary expertise required to deliver high quality antiviral drug candidates. Enabled by world-leading virologists and seasoned drug hunters, unapp will aggressively prosecute a portfolio of 5 projects aiming to discover orally available, safe, and effective drugs against coronaviruses, flavivirus and henipavirus, three major classes of viruses with pandemic potential. The projects portfolio combines approaches targeting well validated drug targets, such as the RNA- dependent RNA polymerases and viral proteases, as well as phenotypic screening, which will allow for the discovery of clinical drug candidates and novel targets that will advance our fundamental understanding of the biology of those viruses. Four scientific cores-virology, high-throughput biology, drug discovery and translational research cores-will provide technological and scientific expertise to support project teams and implement the scientific strategy toward novel antiviral drugs. The unapp will be governed by an administrative core which will be CO-led by the PIS, DR. PEI-yong SHI and DR. Thierry diagana, who have a long track-record of successfully working together. Both PIS have led multiple productive collaborations focused on translational impact and combining public, private and non-governmental organizations. The administrative core will provide integrated decision making in scientific, operational, financial, intellectual property protection, and communication. In collaboration with all project and core leaders, as well as with external input from a scientific advisory board and NIH program officers, they will ensure that the projects portfolio leverages the full spectrum of technologies and capabilities residing in all four scientific cores, capturing synergies across projects through cross-learning and efficient deployment of platforms relevant to multiple viruses. Because of the unique complementarity of the scientific cores and the remarkable synergies of the project portfolio, we fully expect that the unapp will yield exceptional productivity and deliver all the proposed objectives: (1) deliver 3 IND-ready candidates and 3 development candidates, (2) advance antiviral research, and (3) train next-generation drug hunters.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$7,503,323 | |
| Amendment | -$18,849,015 | |
| Amendment | -$18,849,015 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $18,849,015 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $56,163,625 |
Show all 12
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Icahn School Of Medicine At Mount Sinai | $500,000 | |
| Novartis Institutes For Biomedical Research, Inc. | $12,644,486 | |
| Novartis Institutes For Biomedical Research, Inc. | $3,535,626 | |
| Novartis Institutes For Biomedical Research, Inc. | $1,287,625 | |
| Novartis Institutes For Biomedical Research, Inc. | $1,430,113 | |
| Novartis Institutes For Biomedical Research, Inc. | $1,310,595 | |
| Novartis Institutes For Biomedical Research, Inc. | $2,498,738 | |
| Novartis Institutes For Biomedical Research, Inc. | $781,110 | |
| Novartis Institutes For Biomedical Research, Inc. | $472,135 |
Quick answers
Who received award U19AI171413?
U19AI171413 was awarded to University Of Texas Medical Branch At Galveston by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 16, 2022.
How much is award U19AI171413 worth?
$29,811,287 has been obligated on U19AI171413.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award